Retatrutide's first phase 3 trial: 28.7% weight loss and less knee pain

Eli Lilly reported the first phase 3 results for retatrutide, a once-weekly injection that activates GIP, GLP-1 and glucagon receptors. In TRIUMPH-4, which enrolled 445 adults with obesity or overweight and knee osteoarthritis, those on the 12 mg dose lost an average of 28.7% of body weight at 68 weeks, and WOMAC knee pain scores fell by up to 75.8%. Dysesthesia (altered skin sensation) was reported by 20.9% on 12 mg versus 0.7% on placebo.